MONTRÉAL, Nov. 29, 2021 (GLOBE NEWSWIRE) — ExCellThera Inc., a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that new data from hematopoietic stem cell clinical trials using its lead technology, ECT-001, will be presented at the 63rd Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia or virtually. Details of the presentation are as follows:
Date & Time: Saturday, December 11, 2021, 2:00-2:45 p.m. ET
Title: Therapeutic Applications of Expanded HSCs
Session: Scientific Program, Regulators of Hematopoietic Stem Cell Development and Expansion: Bench to Bedside
Presenter: Guy Sauvageau, MD, University of Montreal
Location: Georgia World Congress Center, B304-B305, Level 3
About ExCellThera Inc.
ExCellThera is a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in novel one-time curative therapies for patients with hematologic malignancies and other diseases. ExCellThera’s most advanced technology, ECT-001 Cell Therapy, combines a proprietary molecule, UM171, and an optimized culture system. In pursuit of better treatments for patients, the company is building out its cell expansion and engineering platform, as well as supporting best-in-class clinical trials. excellthera.com
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsAzi is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
